Merkliste
Die Merkliste ist leer.
Der Warenkorb ist leer.
Kostenloser Versand möglich
Kostenloser Versand möglich
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
Development of Gene Therapies
ISBN/GTIN

Development of Gene Therapies

Strategic, Scientific, Regulatory, and Access Considerations
BuchGebunden
Verkaufsrang56inMathematik
CHF240.50

Beschreibung

Development of Gene Therapies: Strategic, Scientific, and Regulatory, and Access Considerations attempts to summarize the current state-of-the-art strategic, scientific, statistical, and regulatory aspects of GTx development.
Weitere Beschreibungen

Details

ISBN/GTIN978-1-032-13655-4
ProduktartBuch
EinbandGebunden
ErscheinungslandUSA
Erscheinungsdatum23.05.2024
Auflage1. A.
ReiheChapman & Hall/CRC Biostatistics Series
Seiten458 Seiten
SpracheEnglisch
MasseBreite 178 mm, Höhe 254 mm
Gewicht1070 g
IllustrationenFarb., s/w. Abb.
Artikel-Nr.27364314
KatalogBuchzentrum
Datenquelle-Nr.45276304
Weitere Details

Reihe

Bewertungen

Autor

Avery McIntosh, Ph.D. is a drug developer working in rare diseases at Pfizer. He received his M.Sc. and Ph.D. in biostatistics from Boston University with a dissertation on Bayesian methods to model household tuberculosis transmission. He has managed teams of statisticians across study phases and in a variety of drug types and disease areas, including neurology, ophthalmology, infectious disease/ global health, hematology, and oncology. He has published peer-reviewed articles on various topics in drug development and biostatistics, including development of cell and gene therapies and qualification of digital endpoints in neurological diseases.

Oleksandr Sverdlov, Ph.D. is a Neuroscience Disease Area Statistical Lead at Novartis. He received B.Sc. in Applied Mathematics from V.N. Karazin Kharkiv National University, Ukraine, M.Sc. in Statistics from University of Maryland, Baltimore County (UMBC), and Ph.D. in Information Technology with Concentration in Statistical Science from George Mason University. He has been actively involved in methodological research and applications of innovative statistical approaches in drug development. He has co-authored over forty refereed articles, edited two monographs, and co-authored a book Mathematical and Statistical Skills in the Biopharmaceutical Industry: A Pragmatic Approach (CRC Press/Chapman & Hall, 2019). His most recent work involves design and analysis of clinical trials evaluating novel digital technologies